Abstract
Background
Since the first description of Hashimoto’s Encephalitis (HE) in 1966 by Lord Brain, the number of reported cases has continued to increase. In addition, cases of status epilepticus have been reported, suggesting a role for intensive care unit (ICU) practitioners in taking care of patients with HE.
Methods
A retrospective cohort study in ICU patients with HE was performed at the University Hospital of Tours, France.
Results
Eight HE cases were admitted to the ICU between 1/1/2000 and 1/1/2012. Herein, we describe the characteristics of the patients, with an emphasis on ICU disease management and its outcome.
Conclusion
ICU practitioners should be aware of this disease, since it can include life-threatening presentations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brain L, Jellinek EH, Ball K. Hashimoto’s disease and encephalopathy. Lancet. 1966;2(7462):512–4.
Chong JY, Rowland LP, Utiger RD. Hashimoto encephalopathy: syndrome or myth? Arch Neurol. 2003;60(2):164–71.
Chaigne B, Beaufils E, Jouan Y, Magnant J, Maillot F, Constans T, et al. Hashimoto’s encephalopathy. Rev Med Interne. 2012;33(7):390–5.
Doe De Maindreville A, Gombert C, Thiriaux A, Chaunu M, Bakchine S. Hashimoto’s encephalopathy: a rare cause of status epilepticus [Article in French]. Rev Neurol. 2013. doi:10.1016/j.neurol.2012.10.014.
Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3–23.
Castillo P, Woodruff B, Caselli R, Vernino S, Lucchinetti C, Swanson J, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol. 2006;63(2):197–202.
Marshall GA, Doyle JJ. Long-term treatment of Hashimoto’s encephalopathy. J Neuropsychiatry Clin Neurosci. 2006;18(1):14–20.
Tamagno G, Celik Y, Simó R, Dihné M, Kimura K, Gelosa G, et al. Encephalopathy associated with autoimmune thyroid disease in patients with Graves’ disease: clinical manifestations, follow-up, and outcomes. BMC Neurol. 2010;10:27.
Archambeaud F, Galinat S, Regouby Y, Magy L, Rebeyrotte I, Vallat JM, et al. Hashimoto encephalopathy. Analysis of four case reports. Rev Med Interne. 2001;22(7):653–9.
Takahashi S, Mitamura R, Itoh Y, Suzuki N, Okuno A. Hashimoto encephalopathy: etiologic considerations. Pediatr Neurol. 1994;11(4):328–31.
Zelaya AS, Stotts A, Nader S, Moreno CA. Antithyroid peroxidase antibodies in patients with high normal range thyroid stimulating hormone. Fam Med. 2010;42(2):111–5.
Ferracci F, Moretto G, Candeago RM, Cimini N, Conte F, Gentile M, et al. Antithyroid antibodies in the CSF: their role in the pathogenesis of Hashimoto’s encephalopathy. Neurology. 2003;60(4):712–4.
Fatourechi V. Hashimoto’s encephalopathy: myth or reality? An endocrinologist’s perspective. Best Pract Res Clin Endocrinol Metab. 2005;19(1):53–66.
Conflict of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chaigne, B., Mercier, E., Garot, D. et al. Hashimoto’s Encephalopathy in the Intensive Care Unit. Neurocrit Care 18, 386–390 (2013). https://doi.org/10.1007/s12028-013-9834-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12028-013-9834-1